newsfilter
← Latest News
GlobeNewswire·

Immunovant Reports Financial Results and Provides Corporate Updates for the Quarter Ended December 31, 2023

Immunovant plans to initiate 4-5 potentially registrational programs for IMVT-1402 over the next fiscal year Immunovant plans to initiate trials in 10 indications for IMVT-1402 over the next two fiscal yearsInitial